ECRONICON OPEN ACCESS

EC PAEDIATRICS
Short Communication

Nerve Transmitters and Receptors Associated with Bipolar Disorder

AJ Russo[1]*, Albert Mensah[2] and Judith Bowman[2]

[1]Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA

[2]Mensah Research Institute, Warrenville, Il, USA

***Corresponding Author:** AJ Russo, Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.

Received: May 12, 2025; **Published:** May 26, 2025

Abstract

Bipolar disorder (BD) is a mood disorder characterized by abnormal neurotransmitter systems. Serotonin and serotonin transporter gene (5-HTTLPR) are associated with this dysfunction. Medications, such as carbamazepine and lamotrigine, can affect dopaminergic signaling and glutamate transmission, both of which are relevant in managing manic and depressive episodes in bipolar disorder. The GABAergic system may also play a critical role in the pathophysiology of bipolar disorder and polymorphisms related to various neurotransmitter receptors, including those for serotonin (5-HT2C) and dopamine (DRD2), have been associated with alterations in mood disorders.

Keywords: *Bipolar Disorder (BD); 5-HTTLPR; Serotonin; Dopamine*

Bipolar disorder (BD) is a complex mood disorder characterized by significant alterations in neurotransmitter systems, particularly those involving serotonin (5-HT), dopamine (DA), and gamma-aminobutyric acid (GABA). Researchers have proposed various hypotheses regarding the biochemical underpinnings of bipolar disorder, focusing on how alterations in these neurotransmitters and their receptor systems contribute to the pathophysiology of the disorder. Understanding the role of neurotransmitters and their corresponding receptors can provide insights into the mechanisms of bipolar disorder and its treatment.

Serotonin dysfunction has been widely implicated in bipolar disorder. The serotonin transporter gene (5-HTTLPR) is central to this dysfunction, as identified in studies exploring genetic polymorphisms associated with affective disorders. Variants of the 5-HTTLPR have been shown to influence the susceptibility and clinical manifestations of bipolar disorder, particularly through the modulation of serotonergic neurotransmission, which is crucial for mood regulation [1,2]. The findings suggest that not only serotonergic pathways but also multiple serotonin receptor subtypes, such as 5-HT2A and 5-HT2C, play roles in the pathology of bipolar disorder, where alterations in serotonin receptor functioning can modulate dopaminergic systems and thereby affect mood stability [3,4].

Furthermore, research indicates that certain medications, such as carbamazepine and lamotrigine, can affect dopaminergic signaling and glutamate transmission, both of which are relevant in managing manic and depressive episodes in bipolar disorder [5]. This aligns with observed changes in dopamine receptor activity, particularly dopamine D2 and D3 receptors. Abnormal dopamine transmission is often correlated with manic episodes, suggesting that effective bipolar disorder management may hinge on modulating dopamine receptor

activity through the use of antipsychotic medication [6,7]. For instance, cariprazine, a dopamine D3 receptor-preferring partial agonist, has shown efficacy in treating depressive symptoms in bipolar disorder, supporting the integral role of dopamine in mood regulation [8].

The GABAergic system also plays a critical role in the pathophysiology of bipolar disorder. Research highlights that alterations in GABA receptor expression, specifically GABA_A receptors, are associated with heightened neuronal excitability and mood dysregulation, contributing to the manic phases of bipolar disorder [9,10]. A deficit in GABAergic signaling could lead to increased neuronal firing, resulting in manic symptoms, while enhanced GABA activity may alleviate depressive symptoms.

Genetic studies further reinforce the complex interplay between neurotransmitters and bipolar disorder. Polymorphisms related to various neurotransmitter receptors, including those for serotonin (5-HT2C) and dopamine (DRD2), have been associated with alterations in mood disorders, including bipolar disorder [11,12]. Functional disruptions in these receptor systems contribute to the clinical symptoms of the disorder. They may influence treatment responses to psychotropic medications, further complicating management strategies for individuals with bipolar disorder [13].

In addition to receptor activity, imaging techniques have underscored the altered neuroreceptor dynamics in individuals with bipolar disorder. Using methods such as SPECT and PET scans, researchers have identified changes in dopamine receptor availability and binding in the brains of manic patients, which could serve as biomarkers for the disorder and offer insights into individualized treatment approaches [7]. These neuroimaging studies suggest that abnormal dopamine transmission during manic phases might prove crucial in refining pharmacotherapy for patients, as evidenced by variations in receptor binding patterns [7].

In summary, bipolar disorder is characterized by a multifaceted interaction of neurotransmitter systems, primarily serotonin, dopamine, and GABA. Genetic, biochemical, and neuroimaging studies broaden our understanding of how these systems become dysregulated, paving the way for more effective interventions and emphasizing the necessity for personalized treatment strategies that address the intricate neurochemical landscape of bipolar disorder.

Bibliography

1. Heiden A., *et al*. "Association studies of candidate genes in bipolar disorders". *Neuropsychobiology* 42.1 (2000): 18-21.

2. Serretti A., *et al*. "Serotonin transporter gene (5-HTTLPR) and major psychoses". *Molecular Psychiatry* 7.1 (2002): 95-99.

3. Aydin IH and El-Mallakh RS. "Concept article: antidepressant-induced destabilization in bipolar illness mediated by serotonin 3 receptor (5ht3)". *Bipolar Disorders* 26.8 (2024): 772-778.

4. Lerer B., *et al*. "Variability of 5-ht2c receptor cys23ser polymorphism among European populations and vulnerability to affective disorder". *Molecular Psychiatry* 6.5 (2001): 579-585.

5. Basselin M., *et al*. "Chronic carbamazepine administration attenuates dopamine d2-like receptor-initiated signaling via arachidonic acid in rat brain". *Neurochemical Research* 33.7 (2008): 1373-1383.

6. Gibbons AS., *et al*. "Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects". *Journal of Affective Disorders* 116.3 (2009): 184-191.

7. Anand A., *et al*. "Brain spect imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients". *American Journal of Psychiatry* 157.7 (2000): 1108-1114.

8. Yatham LN., *et al*. "Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications". *The Primary Care Companion for CNS Disorders* 22.5 (2020): 20m02611.

9. Moradi M., *et al*. "Genes encoding gaba-β and ht1d receptors in bipolar i (manic phase) patients". *Basic and Clinical Neuroscience Journal* 9.2 (2018): 129-134.

10. Fatemi SH., *et al*. "Expression of gabaa α2-, β1- and ε-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder". *Translational Psychiatry* 3.9 (2018): e303.

11. Anguelova M., *et al*. "A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: i. affective disorders". *Molecular Psychiatry* 8.6 (2003): 574-591.

12. Sajatovic M and Fuller M. "Risperidone in the treatment of bipolar mania". *Neuropsychiatric Disease and Treatment* 2.2 (2006): 127-138.

13. Merikangas K., *et al*. "Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative". *Archives of General Psychiatry* 68.3 (2011): 241-251.

Volume 14 Issue 6 June 2025